赛生药业(06600.HK)与零氪科技签署战略合作协议
赛生药业(06600.HK)公布,与零氪科技签署战略合作协议,双方将进一步合力打造创新支付和数字化服务相结合的创新患者服务模式,探索新的药品渠道流通及交付模式,推动双方与顺丰医药的创新药品流通模式合作,不断提升药品的可及性和患者服务水平。
赛生药业总裁兼首席执行官赵宏表示,双方将持续优化创新患者服务模式,不断提升高品质创新药品的可及性,助力国家完善多层次医疗保障体系,从而更好地服务於广大患者,更高效地推动行业创新前行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.